All In Biotech

Drug Trial Radar · NCT07342881

Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

A Phase 1 Non-Randomized, Open-Label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Mar 10, 2026

Primary completion

Jul 29, 2026

Study completion Jul 29, 2026

Sponsor

Lead sponsor
Aligos TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and 2), matched for age, body weight and, to the extent possible, for sex.

Conditions

  • Chronic Hepatitis B Infection

Interventions

  • Pevifoscorvir Sodium (ALG-000184)Drug

    Pevifoscorvir Sodium (ALG-000184) Single oral doses of 100 mg pevifoscorvir sodium

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration time curve [AUC]Time frame: Up to 4 days
  2. Maximum plasma concentration [Cmax]Time frame: Up to 4 Days
  3. Minimum plasma concentration [Cmin]Time frame: Up to 4 Days
  4. C0 [predose]Time frame: Up to 4 days
  5. Half-life [t1/2]Time frame: Up to 4 Days
  6. Time to maximum plasma concentration [Tmax]Time frame: Up to 4 Days
  7. Apparent Clearance (CL/F)Time frame: Up to 4 Days
  8. Apparent Volume of Distribution (V/F)Time frame: Up to 4 Days
  9. Total Amount of Drug Excreted in Urine (Ae)Time frame: Up to 4 Days
  10. Renal Clearance (CLr)Time frame: Up to 4 Days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Orlando Clinical Research Center

    Orlando, Florida

  • Genesis Clinical Trials

    Tampa, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.